Neuland Laboratories · NSE: NEULANDLAB · BSE: 524558
Q4 FY23 results · Jan–Mar 2023
Neuland Laboratories reported revenue from operations of ₹407.07 crore (up 59.1% from Q4 FY22) and net profit of ₹84.54 crore (up 288.2% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 407.07 | 255.87 | +59.1% | 269.25 | +51.2% |
| Other income | 8.06 | 0.63 | 13x | 0.93 | +764.2% |
| Total income | 415.14 | 256.50 | +61.8% | 270.18 | +53.7% |
| Profit before tax | 110.16 | 24.28 | +353.8% | 38.94 | +182.9% |
| Net profit for the period | 84.54 | 21.78 | +288.2% | 30.55 | +176.8% |
| EPS, basic (₹) | 65.90 | 17.01 | +287.4% | 23.81 | +176.8% |
| Net margin (%) | 20.8 | 8.5 | 11.3 |
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 407.07 | 255.87 | +59.1% | 269.25 | +51.2% |
| Other income | 8.06 | 0.63 | 13x | 0.93 | +764.2% |
| Total income | 415.14 | 256.50 | +61.8% | 270.18 | +53.7% |
| Profit before tax | 110.02 | 24.12 | +356.1% | 38.80 | +183.6% |
| Net profit for the period | 84.51 | 21.83 | +287.2% | 30.44 | +177.7% |
| EPS, basic (₹) | 65.87 | 17.01 | +287.2% | 23.72 | +177.7% |
| Net margin (%) | 20.8 | 8.5 | 11.3 |
Consolidated
- Filed with BSE
- 17 May 2023, 14:31 IST
- Board meeting
- 11 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 17 May 2023, 14:31 IST
- Board meeting
- 11 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE